Attention deficit hyperactivity disorder in adults

World Journal of Biological Psychiatry

Volumn 11, Issue 5, 2010, Pages 684-698

  Rösler, Michael ^a   Casas, Miguel ^b   Konofal, Eric ^c   Buitelaar, Jan ^d  

^a Neurozentrum Universit Ä Tsklinikum des Saarlandes   (Germany)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ADHD; Genetics; Pharmacotherapy; Psychosocial intervention; Side effects

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE DERIVATIVE; ATOMOXETINE; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; LISDEXAMFETAMINE; METHYLPHENIDATE; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT; DELAYED RELEASE FORMULATION; PROPYLAMINE;

ADULT; ADULT DISEASE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CHILD; CLINICAL TRIAL; COMORBIDITY; CONTROLLED RELEASE FORMULATION; DAILY LIFE ACTIVITY; DRUG TOLERABILITY; HUMAN; HUMAN RELATION; MEDICAL LITERATURE; MEDLINE; PATIENT COMPLIANCE; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SYMPTOM; AGE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DELAYED RELEASE FORMULATION; DIFFERENTIAL DIAGNOSIS; DRUG ADMINISTRATION; MEDICATION COMPLIANCE; PSYCHOLOGY; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGE FACTORS; AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DELAYED-ACTION PREPARATIONS; DIAGNOSIS, DIFFERENTIAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; MEDICATION ADHERENCE; METHYLPHENIDATE; PROPYLAMINES; TREATMENT OUTCOME;

EID: 77954376727     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2010.483249     Document Type: Review

References (86)

1. Adler LA, Spencer TJ, Milton DR, Moore RJ, Michelson D. 2005. Long-term, open-label study of the safety and effi cacy of ato-moxetine in adults with attention-defi cit/hyperactivity disorder: an interim analysis. J Clin Psychiatry 66(3):294-299.
2. Adler L, Dietrich A, Reimherr FW, Taylor LV, Sutton VK, Bakken R, et al. 2006a. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann Clin Psychiatry 18(2):107-113.
3. Adler LA, Sutton VK, Moore RJ, Dietrich AP, Reimherr FW, Sangal RB, et al. 2006b. Quality of life assessment in adult patients with attention-defi cit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol 26(6):648-652.
4. Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, et al. 2008a. Double-blind, placebo-controlled study of the effi cacy and safety of lisdexamfetamine dimesylate in adults with attention-defi cit/hyperactivity disorder. J Clin Psychiatry 69(9):1364-1373.
5. Adler LA, Spencer T, McGough JJ, Jain H, Muniz R. 2008b. Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. J Attent Disord 12(5):449-459
6. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text revision. Arlington, VA: American Psychiatric Association Publishing Inc.
7. American Psychiatric Association. 2010. DSM-5: Options being considered for ADHD. Available at: http://www.dsm5.org/Proposed%20Revision%20Attachments/ APA%20Options%20 for%20ADHD.pdf (accessed 30 March 2010).
8. Asherson P, Chen W, Craddock B, Taylor E. 2007. Adult attention-defi cit hyperactivity disorder: recognition and treatment in general adult psychiatry. Br J Psychiatry 190:4-5.
9. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, et al. 2006. Long-acting medications for the hyper-kinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15(8):476-495.
10. Bangs ME, Jin L, Zhang S, Desaiah D, Allen AJ, Read HA, et al. 2008. Hepatic events associated with atomoxetine treatment for attention-defi cit hyperactivity disorder. Drug Saf 31(4):345-354.
11. Barkley R, Murphy K, Fischer M. 2007a. ADHD in adults: What the science says. New York: Guilford Press.
12. Barkley RA, Anderson DL, Kruesi M. 2007b. A pilot study of the effects of atomoxetine on driving performance in adults with ADHD. J Atten Disord 10(3):306-316.
13. Biederman J, Faraone SV. 2005. Attention-defi cit hyperactivity disorder. Lancet 366(9481):237-248.
14. Biederman J, Faraone S V. 2006. The effects of attention-defi cit/hyperactivity disorder on employment and household income. MedGenMed 8(3):12.
15. Biederman J, Spencer TJ, Wilens TE, Weisler RH, Read SC, Tulloch SJ. 2005. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 10(12 Suppl 20):16-25. (Pubitemid 43010494)
16. Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M. 2006a. Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community. J Clin Psychiatry 67(4):524-540.
17. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, et al. 2006b. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-defi cit/hyperactivity disorder. Biol Psychiatry 59(9):829-835.
18. Boonstra AM, Oosterlaan J, Sergeant JA, Buitelaar JK. 2005. Executive functioning in adult ADHD: a meta-analytic review. Psychol Med 35(8):1097-1108. (Pubitemid 41103002)
19. Boonstra AM, Kooij JJ, Oosterlaan J, Sergeant JA, Buitelaar JK, Van Someren EJ. 2007. Hyperactive night and day? Actigraphy studies in adult ADHD: a baseline comparison and the effect of methylphenidate. Sleep 30(4):433-442.
20. Bush G, Frazier JA, Rauch SL, Seidman LJ, Whalen PJ, Jenike MA, et al. 1999. Anterior cingulate cortex dysfunction in attention-defi cit/hyperactivity disorder revealed by fMRI and the Counting Stroop. Biol Psychiatry 45(12):1542-1552.
21. Bush G, Valera EM, Seidman LJ. 2005. Functional neuroimaging of attention-defi cit/hyperactivity disorder: a review and suggested future directions. Biol Psychiatry 57(11):1273-1284.
22. Cox DJ, Merkel RL, Penberthy JK, Kovatchev B, Hankin CS. 2004. Impact of methylphenidate delivery profi les on driving performance of adolescents with attention-defi cit/hyperactivity disorder: a pilot study. J Am Acad Child Adolesc Psychiatry 43(3):269-275.
23. de Graaf R, Kessler RC, Fayyad J, ten Have M, Alonso J, Angermeyer M, et al. 2008. The prevalence and effects of adult attention-defi cit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med 65(12):835-842.
24. Dulcan M. 1997. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-defi cit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 36(10 Suppl):85-121S.
25. Eakin L, Minde K, Hechtman L, Ochs E, Krane E, Bouffard R, et al. 2004. The marital and family functioning of adults with ADHD and their spouses. J Atten Disord 8(1):1-10.
26. Ehlis AC, Bahne CG, Jacob CP, Herrmann MJ, Fallgatter AJ. 2008. Reduced lateral prefrontal activation in adult patients with attention-defi cit/hyperactivity disorder (ADHD) during a working memory task: a functional near-infrared spectroscopy (fNIRS) study. J Psychiatr Res 42(13):1060-1067.
27. Ellison-Wright I, Ellison-Wright Z, Bullmore E. 2008. Structural brain change in Attention Defi cit Hyperactivity Disorder iden-tifi ed by meta-analysis. BMC Psychiatry 8:51.
28. Faraone S V. 2008. Lisdexamfetamine dimesylate: the fi rst long-acting prodrug stimulant treatment for attention defi cit/hyperactivity disorder. Expert Opin Pharmacother 9(9): 1565-1574.
29. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. 2004. Meta-analysis of the effi cacy of methylphenidate for treating adult attention-defi cit/hyperactivity disorder. J Clin Psychop-harmacol 24(1):24-29.
30. Faraone SV, Biederman J, Doyle A, Murray K, Petty C, Adamson JJ, et al. 2006a. Neuropsychological studies of late onset and subthreshold diagnoses of adult attention-defi cit/hyperactivity disorder. Biol Psychiatry 60(10):1081-1087.
31. Faraone SV, Biederman J, Spencer T, Mick E, Murray K, Petty C, et al. 2006b. Diagnosing adult attention defi cit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry 163(10):1720-1729; quiz 1859.
32. Fayyad J, De Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, et al. 2007. Cross-national prevalence and correlates of adult attention-defi cit hyperactivity disorder. Br J Psychiatry 190:402-409.
33. Fayed N, Modrego PJ, Castillo J, Davila J. 2007. Evidence of brain dysfunction in attention defi cit-hyperactivity disorder: a controlled study with proton magnetic resonance spectroscopy. Acad Radiol 14(9):1029-1035.
34. Fischer M, Barkley RA, Smallish L, Fletcher K. 2007. Hyperactive children as young adults: driving abilities, safe driving behavior, and adverse driving outcomes. Accid Anal Prev 39(1):94-105.
35. Fried R, Petty CR, Surman CB, Reimer B, Aleardi M, Martin JM, et al. 2006. Characterizing impaired driving in adults with attention-defi cit/hyperactivity disorder: A controlled study. J Clin Psychiatry 67(4):567-574.
36. Gau SS, Kessler RC, Tseng WL, Wu YY, Chiu YN, Yeh CB, et al. 2007. Association between sleep problems and symptoms of attention-defi cit/hyperactivity disorder in young adults. Sleep 30(2):195-201.
37. Gibbins C, Weiss M. 2007. Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults. Curr Psychiatry Rep 9(5):420-426.
38. Goodman DW, Ginsberg L, Weisler RH, Cutler AJ, Hodgkins P. 2005. An interim analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) evaluation of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 10(12 Suppl 20):26-34.
39. Harvey E, Danforth JS, McKee TE, Ulaszek WR, Friedman JL. 2003. Parenting of children with attention-defecit/hyperactivity disorder (ADHD): the role of parental ADHD symptomatology. J Atten Disord 7(1):31-42.
40. Hervey AS, Epstein JN, Curry JF. 2004. Neuropsychology of adults with attention-defi cit/hyperactivity disorder: a meta-analytic review. Neuropsychology 18(3):485-503.
41. Hesslinger B, Tebartz van Elst L, Nyberg E, Dykierek P, Richter H, Berner M, et al. 2002. Psychotherapy of attention defi cit hyperactivity disorder in adults-a pilot study using a structured skills training program. Eur Arch Psychiatry Clin Neurosci 252(4):177-184.
42. Jain N, Hechtman L, Quinn D. 2006. Canadian Attention Defi cit Hyperactivity Disorder Resource Alliance (CADDRA): Canadian ADHD Clinical Practice Guidelines. Toronto: CADDRA.
43. Kemner JE, Lage MJ. 2006. Effect of methylphenidate formulation on treatment patterns and use of emergency room services. Am J Health Syst Pharm 63(4):317-322.
44. Kessler RC, Adler L, Ames M, Barkley RA, Birnbaum H, Greenberg P, et al. 2005. The prevalence and effects of adult attention defi cit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med 47(6):565-572.
45. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. 2006. The prevalence and correlates of adult ADHD in the United States: results from the National Comor-bidity Survey Replication. Am J Psychiatry 163(4):716-723.
46. Kooij JJ, Burger H, Boonstra AM, Van der Linden PD, Kalma LE, Buitelaar JK. 2004. Effi cacy and safety of methylphenidate in 45 adults with attention-defi cit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psy-chol Med 34(6):973-1782
47. Kooij SJJ, Boonstra KA, Swinkels SH, Bekker EM, de Noord I, Buitelaar JK. 2008. Reliability, validity, and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients. J Atten Disord 11(4): 445-458.
48. Kuperman S, Perry PJ, Gaffney GR, Lund BC, Bever-Stille KA, Arndt S, et al. 2001. Bupropion SR vs. methylphenidate vs. placebo for attention defi cit hyperactivity disorder in adults. Ann Clin Psychiatry 13(3):129-134.
49. Makris N, Biederman J, Valera EM, Bush G, Kaiser J, Kennedy DN, et al. 2007. Cortical thinning of the attention and executive function networks in adults with attention-defi cit/hyperac-tivity disorder. Cereb Cortex 17(6):1364-1375.
50. McGough JJ, Barkley RA. 2004. Diagnostic controversies in adult attention defi cit hyperactivity disorder. Am J Psychiatry 161(11):1948-1956.
51. McGough JJ, Smalley SL, McCracken JT, Yang M, Del'Homme M, Lynn DE, et al. 2005. Psychiatric comorbidity in adult attention defi cit hyperactivity disorder: fi ndings from multiplex families. Am J Psychiatry 162(9):1621-1627.
52. Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemela A, Trott GE, et al. 2008. A randomized, placebo-controlled trial of three fi xed dosages of prolonged-release OROS methylphenidate in adults with attention-defi cit/hyperactivity disorder. Biol Psychiatry 63(10):981-989.
53. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, et al. 2003. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53(2): 112-120.
54. Nierenberg AA, Miyahara S, Spencer T, Wisniewski SR, Otto MW, Simon N, et al. 2005. Clinical and diagnostic implications of lifetime attention-defi cit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the fi rst 1000 STEP-BD participants. Biol Psychiatry 57(11):1467-1473.
55. National Institute for Mental Health. 2009. Attention Defi cit Hyperactivity Disorder. Available at: http://www.nimh.nih.gov/health/ publications/attention-deficit-hyperactivity-disorder/complete-index.shtml (accessed August 2009)
56. National Institute for Health and Clinical Excellence. Attention Defi cit Hyperactivity Disorder. Diagnosis and management of ADHD in children, young people and adults. September 2008
57. Newcorn JH. 2008. Cardiovascular safety of ADHD medication treatments. CNS Spectr 13(Suppl 15):5-8.
58. Nissen SE. 2006. ADHD drugs and cardiovascular risk. New Engl J Med 354(14):1445-1448.
59. Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, et al. 2007. Evidence-based guidelines for management of attention-defi cit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharma-col 21(1):10-41.
60. Olfson M, Marcus SC, Zhang HF, Wan GJ. 2007. Continuity in methylphenidate treatment of adults with attention-defi cit/hyperactivity disorder. J Manag Care Pharm 13(7):570-577.
61. Ramos-Quiroga JA, Bosch R, Castells X, Valero S, Nogueira M, Gomez N, et al. 2008. Effect of switching drug formulations from immediate-release to extended-release OROS meth-ylphenidate: a chart review of Spanish adults with attention-defi cit hyperactivity disorder. CNS Drugs 22(7):603-611.
62. Reimer B, D'Ambrosio LA, Coughlin JF, Fried R, Biederman J. 2007. Task-induced fatigue and collisions in adult drivers with attention defi cit hyperactivity disorder. Traffi c Inj Prev 8(3): 290-299.
63. Reimherr FW, Marchant BK, Strong RE, Hedges DW, Adler L, Spencer TJ, et al. 2005. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry 58(2): 125-131.
64. Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK. 2007. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 68(1):93-101.
65. Ribases M, Hervas A, Ramos-Quiroga JA, Bosch R, Bielsa A, Gastaminza X, et al. 2008. Association study of 10 genes encoding neurotrophic factors and their receptors in adult and child attention-defi cit/hyperactivity disorder. Biol Psychiatry 63(10):935-945.
66. Richards TL, Deffenbacher JL, Rosen LA, Barkley RA, Rodricks T. 2006. Driving anger and driving behavior in adults with ADHD. J Atten Disord 10(1):54-64.
67. Rösler M, Retz W, Retz-Junginger P, Hengesch G, Schneider M, Supprian T, et al. 2004. Prevalence of attention defi cit-/hyper-activity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatry Clin Neurosci 254(6):365-371.
68. Rösler M, Fischer R, Ammer R, Ose C, Retz W. 2009. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-defi cit/hyperactivity disorder. Eur Arch Psychiatry Clin Neuro-sci 259(2):120-129.
69. Safren SA, Sprich S, Chulvick S, Otto MW. 2004. Psychosocial treatments for adults with attention-defi cit/hyperactivity disorder. Psychiatr Clin North Am 27(2):349-360.
70. Safren SA, Otto MW, Sprich S, Winett CL, Wilens TE, Biederman J. 2005. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther 43(7):831-842.
71. Seidman LJ, Valera EM, Makris N, Monuteaux MC, Boriel DL, Kelkar K, et al. 2006. Dorsolateral prefrontal and anterior cin-gulate cortex volumetric abnormalities in adults with attention-defi cit/hyperactivity disorder identifi ed by magnetic resonance imaging. Biol Psychiatry 60(10):1071-1080.
72. Sobanski E, Schredl M, Kettler N, Alm B. 2008. Sleep in adults with attention defi cit hyperactivity disorder (ADHD) before and during treatment with methylphenidate: a controlled poly-somnographic study. Sleep 31(3):375-381.
73. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, et al. 2005. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-defi cit/hyperactivity disorder. Biol Psychiatry 57(5):456-463.
74. Spencer TJ, Biederman J, Madras BK, Dougherty DD, Bonab AA, Livni E, et al. 2007a. Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane. Biol Psychiatry 62(9):1059-1061.
75. Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L. 2007b. Effi cacy and safety of dexmethylphenidate extended-release capsules in adults with attention-defi cit/hyperactivity disorder. Biol Psychiatry 61(12):1380-1387.
76. Stevenson CS, Whitmont S, Bornholt L, Livesey D, Stevenson RJ. 2002. A cognitive remediation programme for adults with Attention Defi cit Hyperactivity Disorder. Aust NZ J Psychiatry 36(5):610-616.
77. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, et al. 2003. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-defi cit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 60(2):204-211.
78. Verster JC, Bekker EM, de Roos M, Minova A, Eijken EJ, Kooij JJ, et al. 2008. Methylphenidate signifi cantly improves driving performance of adults with attention-defi cit hyperactivity disorder: a randomized crossover trial. J Psychopharmacol 22(3): 230-237.
79. Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS, et al. 2007. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-defi cit/hyperactivity disorder. Arch Gen Psychiatry 64(8):932-940.
80. Weisler RH, Biederman J, Spencer TJ, Wilens TE. 2005. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 10(12 Suppl 20):35-43. (Pubitemid 43010496)
81. Weisler RH, Biederman J, Spencer TJ, Wilens TE, Faraone SV, Chrisman AK, et al. 2006. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 11(8):625-639.
82. Wender EH. 1995. Attention-defi cit hyperactivity disorders in adolescence. J Dev Behav Pediatr 16(3):192-195.
83. Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, et al. 2003. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 26(10):729-740.
84. Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, et al. 2005. Blood pressure changes associated with medication treatment of adults with attention-defi cit/hyperac-tivity disorder. J Clin Psychiatry 66(2):253-259.
85. Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF. 2005. Validity of the executive function theory of attention-defi cit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry 57(11):1336-1346.
86. Wolraich ML, Doffi ng MA. 2004. Pharmacokinetic considerations in the treatment of attention-defi cit hyperactivity disorder with methylphenidate. CNS Drugs 18(4):243-250.